IL310354A - Water soluble prodrug, conjugates and uses thereof - Google Patents

Water soluble prodrug, conjugates and uses thereof

Info

Publication number
IL310354A
IL310354A IL310354A IL31035424A IL310354A IL 310354 A IL310354 A IL 310354A IL 310354 A IL310354 A IL 310354A IL 31035424 A IL31035424 A IL 31035424A IL 310354 A IL310354 A IL 310354A
Authority
IL
Israel
Prior art keywords
moiety
conjugate
compound
oligo
auristatin
Prior art date
Application number
IL310354A
Other languages
English (en)
Hebrew (he)
Inventor
Doron Shabat
Ronit Satchi-Fainaro
Stanley Sweeney-Lasch
Carl Deutsch
Nir Berger
Original Assignee
Univ Ramot
Merck Patent Gmbh
Doron Shabat
Satchi Fainaro Ronit
Sweeney Lasch Stanley
Carl Deutsch
Nir Berger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Merck Patent Gmbh, Doron Shabat, Satchi Fainaro Ronit, Sweeney Lasch Stanley, Carl Deutsch, Nir Berger filed Critical Univ Ramot
Publication of IL310354A publication Critical patent/IL310354A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL310354A 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof IL310354A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (1)

Publication Number Publication Date
IL310354A true IL310354A (en) 2024-03-01

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310354A IL310354A (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Country Status (7)

Country Link
EP (1) EP4377292A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024532677A (cg-RX-API-DMAC10.html)
CN (1) CN117999254A (cg-RX-API-DMAC10.html)
AU (1) AU2022318483A1 (cg-RX-API-DMAC10.html)
CA (1) CA3226393A1 (cg-RX-API-DMAC10.html)
IL (1) IL310354A (cg-RX-API-DMAC10.html)
WO (1) WO2023007481A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531620A (ja) * 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
KR102710962B1 (ko) * 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
AU2019365238A1 (en) * 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
CN113613679A (zh) * 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法

Also Published As

Publication number Publication date
EP4377292A4 (en) 2026-06-03
AU2022318483A1 (en) 2024-02-22
EP4377292A1 (en) 2024-06-05
CN117999254A (zh) 2024-05-07
WO2023007481A1 (en) 2023-02-02
JP2024532677A (ja) 2024-09-10
CA3226393A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
AU2022204013B2 (en) Targeted delivery of tertiary amine-containing drug substances
JP7257951B2 (ja) 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート
JP7620991B6 (ja) 標的送達及び活性化した免疫刺激性複合体の調製と使用
AU2022204711B9 (en) Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
TWI814699B (zh) 四級胺化妥布賴森(tubulysin)化合物之結合物
TWI900494B (zh) 從生物活性化合物的內化共軛物選擇性釋出藥物
CN112752759A (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途
CN103379912B (zh) 正羧烷基耳他汀及其应用
EP3288593A1 (en) Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer
CN106170303A (zh) 通过半胱天冬酶激活的前体药物
JP2018512376A (ja) 抗体薬物コンジュゲート
IL195236A (en) Aziridinyl-epothilone compounds, use thereof for preparation of a medicament and a process for making a pharmaceutical composition
TW202506105A (zh) 連接子-藥物分子及抗體藥物偶聯物、其製備方法和應用
WO2023007481A1 (en) Water soluble prodrug, conjugates and uses thereof
WO2025077572A1 (zh) 一种用于前药给药系统的可裂解连接体化合物及其制备和应用
WO2025031923A1 (en) Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
HK40111022A (en) Water soluble prodrug, conjugates and uses thereof
US9669106B2 (en) Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
KR20240016231A (ko) 신규 오리스타틴 전구약물
HK40065994A (en) Targeted delivery of tertiary amine-containing drug substances
HK40079820B (en) Targeted delivery of tertiary amine-containing drug substances
HK40104908A (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
TW202613076A (zh) 鏈接子-有效負載、由其作成之抗體-藥物共軛物及其用途
CN121449623A (zh) 一种拓扑异构酶抑制剂及其偶联物的应用
WO2026107097A1 (en) Self-immolative linkers and conjugates thereof